We scan new podcasts and send you the top 5 insights daily.
Rob notes the nivolumab trial presented circulating tumor DNA data and more patients in the nivolumab arm had detectable ctDNA at baseline, a strong poor prognostic factor. He says this is not a full explanation but illustrates unseen imbalances that can appear despite randomization. Such imbalances can swing large trials.
Not all ctDNA clearance is equal. Data from KEYNOTE-361 shows chemotherapy clears ctDNA more frequently (40%) but with poor correlation to outcomes. In contrast, immunotherapy clears ctDNA less often (11%), but those patients who do clear it experience brilliant, more durable outcomes, suggesting a different biological mechanism of response.
The type of treatment inducing ctDNA clearance matters. Clearance from immunotherapy appears to be more permanent and strongly prognostic than clearance from chemotherapy, which can be transient. This suggests immunotherapy may achieve a more profound and lasting elimination of cancer cells versus cytotoxic agents.
In the Serena 6 trial, patients whose circulating tumor DNA (ctDNA) was cleared after switching to camazestrant had a significantly improved overall survival (HR 0.4). This exploratory finding suggests ctDNA monitoring can be a potent early indicator of long-term treatment success, potentially reshaping how therapeutic efficacy is measured long before imaging can.
Niagara's control arm had 60% two-year event-free survival versus about 70% in the negative trials. The discussion says this makes Niagara the highest-risk population, where more events and greater risk can let an immune-therapy benefit show up. That may explain more than drug differences alone.
Unlike immunotherapy, where ctDNA clearance strongly predicts good outcomes, chemotherapy can cause a temporary decrease in ctDNA that doesn't correlate with long-term survival. This "smudging" effect complicates ctDNA interpretation for patients receiving chemo-immunotherapy combinations.
Observational data from the BESPOKE study showed that the survival benefit from adjuvant chemotherapy was only seen in patients who tested positive for ctDNA post-surgery. In contrast, ctDNA-negative patients had overlapping survival curves whether they received chemotherapy or not, questioning its utility for that group.
Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.
The control arm relapse rate in the SUNRISE 2 trial was only ~20%, while in the EV-303/KEYNOTE-905 trial it was ~60%. This huge discrepancy highlights that current clinical staging and selection criteria are poor at identifying patient risk, signaling an urgent need for better stratification tools like ctDNA for more effective clinical trials.
New phase 3 trial data shows that the quantitative level of circulating tumor DNA (ctDNA) is directly proportional to recurrence rates in bladder cancer. Patients with the highest ctDNA levels have the worst outcomes, suggesting a gradient of risk that could be used for more precise patient stratification.
Tom says he is sure that rerunning Niagara, Energize, and the pembrolizumab trial would not produce the same two negatives and one positive. He argues randomized phase 3 trials are imperfect and vulnerable to noise, chance, and unseen imbalances. That should temper how confidently we interpret any single result.